243 related articles for article (PubMed ID: 35982976)
1. Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.
Diamantidis MD; Papadaki S; Hatjiharissi E
Front Oncol; 2022; 12():934008. PubMed ID: 35982976
[TBL] [Abstract][Full Text] [Related]
2. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma.
Kleber M; Ntanasis-Stathopoulos I; Terpos E
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136374
[TBL] [Abstract][Full Text] [Related]
3. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
4. Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).
Nguyen N; Chaudhry S; Totiger TM; Diaz R; Roberts E; Montoya S; Pardo G; Pardo A; Afaghani J; Affer M; Jahn J; Bradley T; Maura F; Kazandjian D; Bilbao D; Chapman J; Landgren O; Hoffman J; Taylor J
NPJ Precis Oncol; 2022 Oct; 6(1):73. PubMed ID: 36261486
[TBL] [Abstract][Full Text] [Related]
5. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
7. Discovery platform for inhibitors of IgH gene enhancer activity.
Dolloff NG
Cancer Biol Ther; 2019; 20(4):571-581. PubMed ID: 30481117
[TBL] [Abstract][Full Text] [Related]
8. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
9. Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).
Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Månsson R; Wagner AK; Alici E
Am J Hematol; 2021 Aug; 96(8):925-933. PubMed ID: 33901326
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
11. [Advances in multiple myeloma molecular biology research].
Hanamura I
Rinsho Ketsueki; 2019; 60(9):1236-1242. PubMed ID: 31597849
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
13. [Molecular Mechanism and Malignant Clonal Evolution of Multiple Myeloma].
Ding F; Zhu P; Wu XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1513-6. PubMed ID: 26524068
[TBL] [Abstract][Full Text] [Related]
14. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
[TBL] [Abstract][Full Text] [Related]
15. In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
Tian E; Sawyer JR; Heuck CJ; Zhang Q; van Rhee F; Barlogie B; Epstein J
Genes Chromosomes Cancer; 2014 Jul; 53(7):549-57. PubMed ID: 24638926
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel PL; Kuehl M
Blood; 2001 Jul; 98(1):217-23. PubMed ID: 11418483
[TBL] [Abstract][Full Text] [Related]
17. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Kumar S; Kaufman JL; Gasparetto C; Mikhael J; Vij R; Pegourie B; Benboubker L; Facon T; Amiot M; Moreau P; Punnoose EA; Alzate S; Dunbar M; Xu T; Agarwal SK; Enschede SH; Leverson JD; Ross JA; Maciag PC; Verdugo M; Touzeau C
Blood; 2017 Nov; 130(22):2401-2409. PubMed ID: 29018077
[TBL] [Abstract][Full Text] [Related]
19. Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene.
Kanda-Akano Y; Nomura K; Fujita Y; Horiike S; Nishida K; Nagai M; Miura I; Nakamura S; Seto M; Iida S; Ueda R; Taniwaki M
Leuk Lymphoma; 2004 Aug; 45(8):1559-67. PubMed ID: 15370207
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma with t(11;14): unique biology and evolving landscape.
Bal S; Kumar SK; Fonseca R; Gay F; Hungria VT; Dogan A; Costa LJ
Am J Cancer Res; 2022; 12(7):2950-2965. PubMed ID: 35968339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]